Abbott Wins European Approval for Latest MitraClip Heart Valve Device
Abbott Laboratories (NYSE: ABT) has scored a fresh victory across the Atlantic Ocean. The company announced Monday that it has been granted a CE Mark for its MitraClip G4, the latest version of its popular heart valve replacement device, which means it is approved for use in the countries of the European Union.
The G4 had already been approved for use in the U.S. by the Food and Drug Administration. It treats mitral regurgitation, a condition in which the mitral valve that sits between the left atrium and left ventricle of the heart fails to close properly. According to Abbott, this is a common heart condition -- among people 75 and older, one in 10 suffer from it.
Image source: Getty Images.
Source Fool.com
